Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc.
The acquisition involves all issued and outstanding common shares of Repare Therapeutics Inc.
The approval was given at a special meeting of shareholders held on January 16, 2026.
Approval of Acquisition
Shareholders approved the acquisition by XenoTherapeutics, Inc.
Resolution Details
Special resolution on compensation and voluntary liquidation were also approved by shareholders.
Arrangement Process
The arrangement is subject to the approval of the Superior Court of Québec and other closing conditions.
- The completion of the arrangement is expected around January 28, 2026, pending court approval.
- Repare Therapeutics specializes in precision oncology treatments, while XenoTherapeutics focuses on xenotransplantation research.
The approval of the acquisition marks a significant milestone for Repare Therapeutics Inc. and sets the stage for future collaborations with XenoTherapeutics, Inc.